LinkedIn·Wednesday, 29 July 2026·28d ago

𝗕𝗮𝘁𝗰𝗵-𝘁𝗼-𝗯𝗮𝘁𝗰𝗵 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝘀 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝘀𝘁𝘂𝗯𝗯𝗼𝗿𝗻 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 𝗶𝗻 𝗖𝗚𝗧…

Antleron

2,980 followers

𝗕𝗮𝘁𝗰𝗵-𝘁𝗼-𝗯𝗮𝘁𝗰𝗵 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝘀 𝗼𝗻𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗺𝗼𝘀𝘁 𝘀𝘁𝘂𝗯𝗯𝗼𝗿𝗻 𝗽𝗿𝗼𝗯𝗹𝗲𝗺𝘀 𝗶𝗻 𝗖𝗚𝗧 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴. Even when the average process performs well, excessive variability can lead to out-of-specification batches and reduced manufacturing robustness. Understanding what's driving that variability usually requires extensive lab work. And because only limited material is available per donor, testing enough conditions to isolate the real drivers is rarely feasible. 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘆𝗼𝘂 𝗰𝗼𝘂𝗹𝗱 𝗾𝘂𝗮𝗻𝘁𝗶𝗳𝘆 𝘄𝗵𝗮𝘁'𝘀 𝗿𝗲𝗮𝗹𝗹𝘆 𝗱𝗿𝗶𝘃𝗶𝗻𝗴 𝘁𝗵𝗮𝘁 𝘃𝗮𝗿𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗻𝗱 𝗸𝗻𝗼𝘄 𝗲𝘅𝗮𝗰𝘁𝗹𝘆 𝘄𝗵𝗲𝗿𝗲 𝘁𝗶𝗴𝗵𝘁𝗲𝗿 𝗰𝗼𝗻𝘁𝗿𝗼𝗹 𝘄𝗶𝗹𝗹 𝗽𝗮𝘆 𝗼𝗳𝗳? Validated hybrid models, deployed on Antleron Nexus, make that possible. By capturing both process dynamics and variability across a representative donor population, you can: • Run thousands of virtual experiments in silico, going far beyond what limited donor material allows in the lab • Quantify how uncontrolled process parameters and material attributes drive your CQA variability • Prioritize control strategies by identifying exactly which parameters and attributes require tighter control to secure the process • Focus laboratory work on targeted, high-impact experimental validation Compared to traditional robustness programs, Antleron's control strategy optimization application can reduce development timelines from 6–12 months to 4–6 months, while reducing the number of physical experiments by 70–90%, depending on the application. Curious what's really driving uncontrolled variability in your process? Let's talk. Antleron Jan Schrooten #AntleronNexus #bioprocess #cgt #atmp #processdevelopment #digitaltwins #cmc #biomanufacturing